Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuronetics (STIM) Total Liabilities (2016 - 2025)

Neuronetics (STIM) has disclosed Total Liabilities for 10 consecutive years, with $114.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 76.26% to $114.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $114.1 million, a 76.26% increase, with the full-year FY2024 number at $109.1 million, up 33.64% from a year prior.
  • Total Liabilities was $114.1 million for Q3 2025 at Neuronetics, up from $103.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $114.1 million in Q3 2025 to a low of $50.3 million in Q1 2021.
  • A 5-year average of $69.9 million and a median of $56.2 million in 2022 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: decreased 3.1% in 2021, then soared 76.26% in 2025.
  • Neuronetics' Total Liabilities stood at $56.0 million in 2021, then rose by 6.74% to $59.8 million in 2022, then skyrocketed by 36.47% to $81.6 million in 2023, then soared by 33.64% to $109.1 million in 2024, then increased by 4.58% to $114.1 million in 2025.
  • Per Business Quant, the three most recent readings for STIM's Total Liabilities are $114.1 million (Q3 2025), $103.1 million (Q2 2025), and $102.5 million (Q1 2025).